• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CTMX

CTMX

CytomX Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.22

+0.06 (+1.90%)

Rating:C

Company Profile

CEO

Sean A. McCarthy

IPO Date

2015-10-08

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.22

Prev. Close

$3.16

Day Low

$3.17

Day High

$3.30

52W Low

$1.72

52W High

$8.21

Market Cap

$0.52B

Volume

3.53M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

17.1%

Avg Negative

13.3%

Avg Neutral

69.6%

News Feed

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/8/2021·↓ negative

CytomX Therapeutics (CTMX) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research·8/5/2021·↑ positive

CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research·7/29/2021·↑ positive

CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

GlobeNewsWire·7/29/2021·↑ positive

Here's Why CytomX Therapeutics (CTMX) is Poised for a Turnaround After Losing 15.8% in 4 Weeks

Zacks Investment Research·7/14/2021·↓ negative

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021

GlobeNewsWire·4/29/2021·↑ positive

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewsWire·4/14/2021·↑ positive

CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021

GlobeNewsWire·3/24/2021·↑ positive

Moving Average Crossover Alert: CytomX Therapeutics (CTMX)

Zacks Investment Research·3/2/2021·↑ positive